Managing Director & Founder
Richard has been covered in Forbes magazine where he explained his experience in modern precision medicine and that it’s now possible to begin tailoring treatments for cancer, heart disease, stroke and other serious diseases by analysing what makes some patients respond better than others. Richard has worked with distinguished scientists and medical practitioners at the frontlines of healthcare. He believes a comprehensive approach to Risk, Prevention, Diagnosis and Treatment requires easy-to-use rapid deployment medical devices, that can acquire key biometric data, coupled with molecular DNA data will improve lives significantly. Delivering these benefits will require ntelligent software technology to interpret the clinical implications of these diverse information sources. Ultimately by predicting and preventing serious diseases and ensuring the right treatments are available to patients faster, with a higher degree of confidence that the treatments will work.
This potential impact on healthcare inspires and drives Richard’s deep personal commitment to deliver his vision through Biosignals Dx. Richard draws on a unique set of skills and experience from 15 years of board and CEO roles with medical device and precision medicine companies. Prior to that a long executive career at Oracle Corporation with global responsibilities for products with $100M+ revenues. He also founded the advisory board and was CIO at iSelect Limited which listed on the ASX in June 2013.
MB ChB MD (Otago) FRACP FCSANZ
Cardiologist & Non-executive Director
A graduate of University of Otago, Stephan gained his post-graduate Doctor of Medicine by research work at The Princess Margaret Hospital, Christchurch, NZ. After completing his Interventional Fellowship (Percutaneous Coronary Interventions) at Royal Perth Hospital, WA, Stephan was appointed as Consultant Cardiologist at Launceston General Hospital, Tasmania. Stephan’s expertise in invasive cardiac techniques led him to establish the invasive cardiac services at Launceston General Hospital. He implemented the hospital’s cardiac catheterisation and permanent pacemaker implantation services. Stephan had a leading role in the development and implementation of the Cardiac Services at St John of God Geelong Hospital. He has been a key advisor to the hospital’s Cardiac Catheterisation and Interventional Cardiology programmes and Cardiac Care Unit. Stephan’s professional affiliations include Fellow Royal Australasian College of Physicians and Fellow Cardiac Society of Australia and New Zealand. Stephan is an Adjunct Clinical Associate Professor at University of Notre Dame Australia and is an active clinical co-ordination and teacher for the UNDA Melbourne Clinical School
Chief Science Officer
Christopher is a commercial data scientist with a background in medical biotechnology and mathematics. With over ten years of experience at the nexus between new and emerging technologies in molecular biology, bioinformatics, big data and new models of genomic analysis for clinical use through AI and Machine Learning. Chris implemented the unique codon-context DNA algorithm for GMDx Genomics which is now capable of predicting responders/non-responders to immunotherapy drugs and predicting Cancer progression with up to 99% accuracy.
Prior to GMDx, Chris worked on a range of genomics and bioinformatics projects in conjunction with Applied Precision Medicine Pty Ltd and Appistry LLC in the US. These projects included collaboration with key US genomic scientists from Washington University (St. Louis) who had contributed to the original mapping of the human genome. Chris worked locally supporting Appistry’s genomic analysis appliances and software pipelines in Australia with GeneWorks, QIMR, Monash University, University of Melbourne, University of Western Australia and the Australian Department of Primary Industries. Through a collaboration with GeneWorks, Chris consulted to Pfizer on bioinformatics relating to gene expression and his work enabled a new drug approach which was ultimately patented by Pfizer.
Recently Chris has enabled early work on ECG pre-processing and genetics associated with arrhythmias. He holds a Bachelor of Biotechnology with Honors from Monash University.
Head of Product Engineering
Lexie is an experienced Biomedical Engineer, covering the end-to-end process of developing medical devices, including Intellectual Property strategy, regulatory strategy and commercialisation strategy. Lexie contributed to initial requirements, established development and manufacturing for the Biosignals Diagnostics ecgme device in China. She is a key contributor to the design and development of the future flagship product (the advanced multi-function monitor). Lexie has a Bachelor of Biomedical Engineering, from Beijing University of Technology and a Master of Biomedical Engineering from Melbourne University. Lexie is also a certified English – Chinese translator.
AI and Data Sciences Engineer
Renee is a competent young professional bringing 2 years of practical experience, in acquiring, interpreting and analysing data in a fast-paced environment to deliver complex data analysis outcomes including predictive modelling. Renee has extensive skills in AI languages such as Python and R with deep understanding of the application of machine learning in the clinical healthcare context. Renee is currently working on a major project at Monash University ”Monitoring health and wellbeing of seniors using unobstructive sensors” where she has developed computational models for the automatic continuous assessment of functional decline and onset of medical conditions. Renee is a certified English – Chinese translator.